Judge Appoints 2 LPR Attorneys to Leadership Roles in Insulin Pricing Multidistrict Litigation

December 07, 2023 06:09 PM AEDT | By EIN Presswire

Google News:

Judge Appoints 2 LPR Attorneys to Leadership Roles in Insulin Pricing Multidistrict Litigation — Image source: EIN Presswire

Recent News

Fed Daly eyes fall for possible policy shift

Fifth Third Announces Three-Year, $20M Investment in North Nashville

Inogen Alliance Associate Awards: Environment Analyst Sustainability D...

New Zealand Construction Report 2025: Output to Contract by 1% Due to...

PENSACOLA, FL, U.S.A., December 7, 2023 /EINPresswire.com/ -- The nationally recognized mass tort law firm Levin Papantonio Rafferty (LPR) announces that LPR Attorney Troy Rafferty has been appointed as Co-Lead Counsel for the State AG Track, and LPR Attorney Brandon Bogle has been appointed as Co-Lead Counsel for the Self-Funded Payer Track in the Insulin Pricing multidistrict litigation (MDL No. 3080).

Recommendations for the appointment of Lead Counsel, Executive and Steering Committees, and Liaison Counsel were submitted on November 27, 2023, by all parties in the MDL.

The State Attorney General Track will include lawsuits brought on behalf of states.

"People assume insulin prices are high because the drug is costly to make. Really, the only thing driving up prices is greed," Rafferty said. "It's costing just about every State, which rains down on taxpayers. Most importantly, it costs lives."

The Self-Funder Payer Track will comprise actions brought individually on behalf of self-funded payers or self-funded payer groups. This includes local governments, like counties, cities, schools, and non-profit organizations (among others) that pay for prescription drugs provided to health plan members who have prescription drug coverage.

Bogle said it's high time for these entities to recover decades of exorbitant costs.

“Cities and counties across this country have been paying outsized premiums from their dwindling budgets on insulin and other type 2 diabetes drugs for their employees," Bogle said. "I personally look forward to recouping those ill gotten gains from the defendants in this case.”

About the Insulin Pricing MDL

On August 4, 2023, the Judicial Panel on Multidistrict Litigation (JPML) created an MDL for insulin pricing lawsuits. The JPML issued a Transfer Order to centralize lawsuits alleging that drug manufacturers and pharmacy benefit manufacturers (PBMs) engaged in an unfair and deceptive conspiracy to orchestrate an insulin pricing scheme.

Defendants in these actions include insulin manufacturers Eli Lilly and Company, Novo Nordisk, Inc., and Sanofi-Aventis U.S. LLC, and, on the PBM side, CVS Caremark, Express Scripts, Optum Rx, and their various corporate affiliates.

LPR law firm has filed insulin price fixing lawsuits against insulin manufacturers and pharmacy benefit managers (PBMs) on behalf of the Arizona Attorney General; Lake County, Illinois (Case No. 1:23-cv-2402); City of Cleveland (Case Number: 1:2023cv01417); Monmouth County, New Jersey (Case Number: 3:2023cv03916); Albany County, New York (Case Number: 1:2022cv00981); and others.

Sara Stephens
Levin Papantonio Rafferty
+1 281-744-6560
email us here
Visit us on social media:
Facebook
Twitter
LinkedIn
Instagram
YouTube

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.